HIV SeropositivityHIV InfectionsHIV SeroprevalenceAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveAnti-Retroviral AgentsSubstance Abuse, IntravenousHIV-1Sexual BehaviorRisk FactorsDrug Resistance, ViralCD4 Lymphocyte CountViral LoadSeroepidemiologic StudiesReverse Transcriptase InhibitorsHIV Protease InhibitorsBenzoxazinesZidovudineDrug Resistance, Multiple, ViralAcquired Immunodeficiency SyndromeNevirapineHIVInfectious Disease Transmission, VerticalHIV Reverse TranscriptaseIndinavirRitonavirLopinavirPregnancy Complications, InfectiousStavudineOrganophosphonatesHIV ProteaseHIV Fusion InhibitorsRNA, ViralLamivudineNelfinavirPyrimidinonesDrug Therapy, CombinationSouth AfricaAIDS-Related Opportunistic InfectionsAdenineUgandaCohort StudiesMedication AdherenceIntegrase InhibitorsDidanosineHIV SeronegativityHIV-Associated Lipodystrophy SyndromePrevalenceTreatment FailureSaquinavirZimbabweAntibodies, ViralViremiaHIV Integrase InhibitorsAfrica South of the SaharaPatient ComplianceCross-Sectional StudiesVirus ReplicationGenotypePregnancyDideoxynucleosidesCD4-Positive T-Lymphocytespol Gene Products, Human Immunodeficiency VirusAntibodies, BacterialHIV Wasting SyndromeTreatment OutcomeChlamydophila pneumoniaeDrug MonitoringImmunoglobulin GProspective StudiesMalawiChlamydophila InfectionsMutationOxazinesSerologic TestsBrazilDrug InteractionsCyclohexanesEnzyme-Linked Immunosorbent AssayDeveloping CountriesRetrospective StudiesTime FactorsGenes, polCommission on Professional and Hospital ActivitiesInfant, NewbornDrug Administration ScheduleDrugs, GenericPyrrolidinonesLipodystrophyAntiviral AgentsIncidencePlasmaZalcitabineHIV Envelope Protein gp41CoinfectionLongitudinal StudiesProtease InhibitorsHelicobacter pyloriHelicobacter InfectionsHepatitis C